Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

pharmaand GmbH

Home Clinical Trial Sponsors and Organizationspharmaand GmbH

pharmaand GmbH

Taborstraße 1, Wien, Austria

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

29

7 active

Approvals

32

Total approvals

Agencies

5

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

15

51.7%

Phase 2

7

24.1%

Phase 3

6

20.7%

Trial Status Distribution

Active, not recruiting

7

24.1%

Completed

17

58.6%

Recruiting

1

3.5%

Terminated

4

13.8%

Clinical Trials

Trials sponsored by this organization (29)

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Mar 202134 participants

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Jan 202083 participants

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Dec 20198 participants

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

Nov 2019248 participants

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Aug 20191 participant

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Jun 201925 participants

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Apr 201936 participants

Blinded, Placebo-Controlled Study to investigate the safety and efficacy of Rucaparib and Nivolumab as Maintenance Treatment in Patients with Ovarian Cancer who have responded to a Platinum-Based Chemotherapy

Active, not recruiting

Dec 20181,000 participants

Page 1 of 4

Approvals

Approvals by Agency

FDA

Food and Drug Administration

4

Approvals

EMA

European Medicines Agency

6

Approvals

CANADA

Health Canada

1

Approvals

EMC

Electronic Medicines Compendium

8

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

13

Approvals

Recent Approvals

Rubraca 200 mg film-coated tablets

Farydak 20mg hard capsules

Farydak 15mg hard capsules

Pegasys 135 micrograms solution for injection in pre-filled syringe

Rubraca 250 mg film-coated tablets

Emselex 7.5mg prolonged-release tablets

Rubraca 300 mg film-coated tablets

Emselex 15mg prolonged-release tablets

News

No news articles found

On this page

Overview
Clinical Trials29
Approvals32
News

Back to Organizations